[Treatment of local low/intermediate risk prostate cancer with low dose rate brachytherapy: a report of 133 cases at a single center].
OBJECTIVE
To investigate the safety and efficacy of low dose rate brachytherapy in local low and intermediate risk prostate cancer patients.


METHODS
All 133 local prostate cancer patients were included and divided into low and intermediate risk groups respectively according to Memorial Sloan Kettering Group (MSKG) definition followed by brachytherapy. All the data including prostatic specific antigen (PSA), international prostatic symptomatic score (IPSS), post-operation complications and image evaluation were collected and recorded.


RESULTS
The average radiation dose delivered to 90% of the prostate (D90) of (152.0±17.3) Gy was performed in the patients with a mean pre-operation PSA level of (13.45±7.1) μg/L and prostate volume of (44.37±21.43) mL. Neoadjuvant therapy was performed in 24 patients with prostate volume larger than 60 mL for 3-6 months. There was no difference in the mean age, prostate volume and D90 between low risk group and intermediate risk group. The mean IPSS reached its peak at the end of the 2nd month post-brachytherapy and compared with the baseline at the end of the 4th month. PSA failure occurred at the end of the mean 31.7 months in 4 patients during the follow-up (1 in low risk group and 3 in intermediate risk group) and no metastasis occurred.


CONCLUSIONS
Lower urinary tract symptom (LUTS) is the most common complication post-operation. Brachytherapy associates with an encouraging tumor progress-free survival in local low and intermediate risk prostate cancer patients.
Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Feng-bo
FB
Zhang
Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Yuan
Y
Du
Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Qiang
Q
Shao
Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Ye
Y
Tian
D001918:Brachytherapy; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000532:radiotherapy*
D017430:Prostate-Specific Antigen